Gaboxadol
From Wikipedia, the free encyclopedia
| Systematic (IUPAC) name | |
|---|---|
| 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3(2H)-one | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 64603-91-4 |
| ATC code | None |
| PubChem | CID 3448 |
| ChemSpider | 3330 |
| UNII | K1M5RVL18S |
| KEGG | D04282 |
| ChEMBL | CHEMBL312443 |
| Chemical data | |
| Formula | C6H8N2O2 |
| Mol. mass | 140.14 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck[1]. In March, 2007, Merck and H. Lundbeck cancelled work on the drug, citing safety concerns and the failure of an efficacy trial. It acts on the GABA system, but in a very different way from benzodiazepines and Z-drugs (zolpidem, zaleplon, etc).[citation needed] Lundbeck states that gaboxadol also increases deep sleep (stage 4).
[edit] See also
[edit] References
- ^ US Patent 4278676 - Heterocyclic compounds
[edit] External links
- MeSH 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol
- H. Lundbeck Website
- Medical News Today article
- Report of cancellation of development.
|
|
| This sedative-related article is a stub. You can help Wikipedia by expanding it. |

